During the past decade, PMG Research of Wilmington conducted 44 clinical trials. In the 10-year time frame, 44 clinical trials started and 33 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 25 clinical trials were completed. i.e. 147.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "PMG Research of Wilmington" #1 sponsor was "Eli Lilly and Company" with 8 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "Pfizer" with 3 trials sponsored, "Bayer" with 2 trials sponsored and "Esperion Therapeutics, Inc." with 2 trials sponsored. Other sponsors include 31 different institutions and companies that sponsored additional 36 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "PMG Research of Wilmington" #1 collaborator was "Allergan Sales, LLC" with 2 trials as a collaborator, "Duke Clinical Research Institute" with 2 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Parexel" with 2 trials as a collaborator and "AbCellera Biologics Inc." with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "PMG Research of Wilmington" are "Migraine" (4 trials), "Idiopathic Pulmonary Fibrosis" (3 trials), "Type 2 Diabetes" (3 trials), "Acne Vulgaris" (2 trials) and "Arthritis, Rheumatoid" (2 trials). Many other conditions were trialed in "PMG Research of Wilmington" in a lesser frequency.

Most popular intervention types in "PMG Research of Wilmington" are "Drug" (47 trials), "Other" (7 trials), "Biological" (5 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Tirzepatide" (3 trials), "Baricitinib" (2 trials), "CC" (2 trials) and "Dihydroergotamine" (2 trials). Other intervention names were less common.

The vast majority of trials in "PMG Research of Wilmington" are 51 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "PMG Research of Wilmington". undefined are not yet recruiting, 1 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 41 completed trials in PMG Research of Wilmington, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in PMG Research of Wilmington, 2 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 3 trials that are defined as “Not Applicable".